{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T05:04:19Z","timestamp":1779253459417,"version":"3.51.4"},"reference-count":21,"publisher":"American Psychiatric Association Publishing","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AJP"],"published-print":{"date-parts":[[1998,1,1]]},"DOI":"10.1176\/ajp.155.1.36","type":"journal-article","created":{"date-parts":[[2014,12,17]],"date-time":"2014-12-17T19:53:32Z","timestamp":1418846012000},"page":"36-42","source":"Crossref","is-referenced-by-count":163,"title":["Double-Blind, Fixed-Dose, Placebo-Controlled Study of Paroxetine in the Treatment of Panic Disorder"],"prefix":"10.1176","volume":"155","author":[{"given":"James C.","family":"Ballenger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David E.","family":"Wheadon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Bushnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan P.","family":"Gergel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"230","reference":[{"key":"R155173","unstructured":"Davidson J, Lydiard RB, McCann U, Pollack M, Rosenbaum JF: Algorithm for the treatment of panic disorder with agoraphobia. Psychopharmacol Bull 1995; 31:457\u2013507"},{"key":"R155175","doi-asserted-by":"crossref","unstructured":"Oehrberg S, Christiansen PE, Behnke K, Borup AL, Severin B, Soegaard J, Calberg H, Judge R, Ohrstrom JK, Manniche PM: Paroxetine in the treatment of panic disorder: a randomised, double-blind, placebo-controlled study. Br J Psychiatry 1995; 167:374\u2013379","DOI":"10.1192\/bjp.167.3.374"},{"key":"R155176","doi-asserted-by":"crossref","unstructured":"Black DW, Wesner R, Bowers W, Gabel J: A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Arch Gen Psychiatry 1993; 50:44\u201350","DOI":"10.1001\/archpsyc.1993.01820130046008"},{"key":"R155177","doi-asserted-by":"crossref","unstructured":"Den Boer JA, Westenberg HG: Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder: a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 1988; 3:59\u201374","DOI":"10.1097\/00004850-198801000-00005"},{"key":"R155178","doi-asserted-by":"crossref","unstructured":"Hoehn-Saric R, McLeod DR, Hipsley PA: Effect of fluvoxamine on panic disorder. J Clin Psychopharmacol 1993; 13:321\u2013326","DOI":"10.1097\/00004714-199310000-00004"},{"key":"R155179","doi-asserted-by":"crossref","unstructured":"Gorman JM, Liebowitz MR, Fyer AJ, Goetz D, Campeas RB, Fyer MR, Davies SO, Klein DF: An open trial of fluoxetine in the treatment of panic attacks. J Clin Psychopharmacol 1987; 7:329\u2013332","DOI":"10.1097\/00004714-198710000-00007"},{"key":"R1551710","doi-asserted-by":"crossref","unstructured":"Schneier FR, Liebowitz MR, Davies SO, Fairbank J, Hollander E, Campeas R, Klein DF: Fluoxetine in panic disorder. J Clin Psychopharmacol 1990; 10:119\u2013121","DOI":"10.1097\/00004714-199004000-00007"},{"key":"R1551712","doi-asserted-by":"crossref","unstructured":"Marks IM, Matthews HM: Brief standard self-rating for phobic patients. Behav Res Ther 1979; 17:263\u2013267","DOI":"10.1016\/0005-7967(79)90041-X"},{"key":"R1551713","doi-asserted-by":"crossref","unstructured":"Hamilton M: The assessment of anxiety states by rating. Br J Med Psychol 1959; 32:50\u201355","DOI":"10.1111\/j.2044-8341.1959.tb00467.x"},{"key":"R1551714","doi-asserted-by":"crossref","unstructured":"Montgomery SA, \u00c2sberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382\u2013389","DOI":"10.1192\/bjp.134.4.382"},{"key":"R1551718","doi-asserted-by":"crossref","unstructured":"Keller MB, Hanks DL: Course and outcome in panic disorder. Prog Neuropsychopharmacol Biol Psychiatry 1993; 17:551\u2013570","DOI":"10.1016\/0278-5846(93)90005-D"},{"key":"R1551719","doi-asserted-by":"crossref","unstructured":"Mavissakalian MR, Perel JM: Imipramine treatment of panic disorder with agoraphobia: dose ranging and plasma level-response relationships. Am J Psychiatry 1995; 152:673\u2013682","DOI":"10.1176\/ajp.152.5.673"},{"key":"R1551720","doi-asserted-by":"crossref","unstructured":"Lesser IM, Lydiard RB, Antel E, Rubin RT, Ballenger JC, DuPont R: Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia. Am J Psychiatry 1992; 149:1556\u20131562","DOI":"10.1176\/ajp.149.11.1556"},{"key":"R1551722","doi-asserted-by":"crossref","unstructured":"Mavissakalian M: Male and female agoraphobia: are they different? Behav Res Ther 1985; 23:469\u2013471","DOI":"10.1016\/0005-7967(85)90175-5"},{"key":"R1551723","doi-asserted-by":"crossref","unstructured":"Ballenger JC, Burrows G, DuPont RL Jr, Lesser JM, Noyes R Jr, Pecknold JC, Rifkin A, Swinson RP: Alprazolam in panic disorder and agoraphobia: results from a multicenter trial, I: efficacy in short-term treatment. Arch Gen Psychiatry 1988; 45:413\u2013422","DOI":"10.1001\/archpsyc.1988.01800290027004"},{"key":"R1551724","doi-asserted-by":"crossref","unstructured":"Schweizer E, Patterson W, Rickels K, Rosenthal M: Double-blind, placebo-controlled study of a once-a-day, sustained-release preparation of alprazolam for the treatment of panic disorder. Am J Psychiatry 1993; 150:1210\u20131215","DOI":"10.1176\/ajp.150.8.1210"},{"key":"R1551726","unstructured":"Amsterdam JD, Hornig-Rohan M, Maislin G: Efficacy of alprazolam in reducing fluoxetine-induced jitteriness in patients with major depression. J Clin Psychiatry 1994; 55:394\u2013400"},{"key":"R1551728","doi-asserted-by":"crossref","unstructured":"Mavissakalian MR, Perel JM: Imipramine dose-response relationship in panic disorder with agoraphobia: preliminary findings. Arch Gen Psychiatry 1989; 46:127\u2013131","DOI":"10.1001\/archpsyc.1989.01810020029006"},{"key":"R1551729","unstructured":"Noyes R Jr, Garvey MJ, Cook BL, Samuelson L: Problems with tricyclic antidepressant use in patients with panic disorder or agoraphobia: results of a naturalistic follow-up study. J Clin Psychiatry 1989; 50:163\u2013169"},{"key":"R1551730","doi-asserted-by":"crossref","unstructured":"Boyer W: Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis. Int Clin Psychopharmacol 1995; 10:45\u201349","DOI":"10.1097\/00004850-199503000-00006"},{"key":"R1551732","doi-asserted-by":"crossref","unstructured":"Frank E, Kupfer DJ, Perel JM: Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990; 47:1093\u20131099","DOI":"10.1001\/archpsyc.1990.01810240013002"}],"container-title":["American Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/psychiatryonline.org\/doi\/10.1176\/ajp.155.1.36","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T15:55:54Z","timestamp":1722182154000},"score":1,"resource":{"primary":{"URL":"https:\/\/psychiatryonline.org\/doi\/10.1176\/ajp.155.1.36"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,1,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1998,1,1]]}},"alternative-id":["10.1176\/ajp.155.1.36"],"URL":"https:\/\/doi.org\/10.1176\/ajp.155.1.36","relation":{},"ISSN":["0002-953X","1535-7228"],"issn-type":[{"value":"0002-953X","type":"print"},{"value":"1535-7228","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,1,1]]}}}